Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib and Combined Oral Contraceptive PK Study in Healthy Females
NCT07539090Phase 1Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vimseltinib, sponsored by Deciphera Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Drug Concentration, Area Under the Plasma Concentration-Time Curve from Time 0 up to Time t and 1 more. Started Jun 2026; status: completed.
02
Drugs
vimseltinib
Beyond the preview
Go deeper on NCT07539090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539090.